QuidelOrtho Announces Share Offering Amid Strategic Shift in Ownership Structure

QuidelOrtho's Strategic Shift: Navigating Shareholder Changes

QuidelOrtho Corporation, a prominent player in the in vitro diagnostics industry, announces a secondary offering of 8,260,183 shares of its common stock. This transaction is initiated by Carlyle Partners VI Cayman Holdings, L.P., the Selling Stockholder, and is designed exclusively for their benefit. Importantly, QuidelOrtho does not participate in the sale of these shares nor will it receive any proceeds from this offering. This development highlights a significant shift in the ownership structure of the company, as the Selling Stockholder will completely divest its shares and subsequently lose its rights under the Principal Stockholders Agreement, including the ability to nominate members to QuidelOrtho's Board of Directors.

The secondary offering is set to close on November 21, 2024, pending customary conditions. Goldman Sachs & Co. LLC acts as the sole underwriter for this offering, which will be made available to the public at a fixed price that may fluctuate without prior notice. The offering is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). As such, prospective investors are encouraged to review the detailed prospectus and related documents to understand the terms and implications of this offering.

This strategic move by the Selling Stockholder represents a pivotal moment for QuidelOrtho as it continues to expand its presence in the diagnostics market. The termination of the Principal Stockholders Agreement could lead to a shift in governance and strategy, potentially allowing for new perspectives on the company's direction. As QuidelOrtho navigates these changes, it remains focused on its core mission of delivering innovative diagnostic solutions that improve patient outcomes.

In addition to the offering, the company emphasizes that this announcement does not constitute an offer to sell or a solicitation to buy the securities in any jurisdiction where such actions would violate local laws. QuidelOrtho also includes cautionary notes regarding forward-looking statements, suggesting that actual results may deviate from those projected. This underscores the company's commitment to transparency and due diligence as it maneuvers through the complexities of capital markets.